92 results on '"Lysák D"'
Search Results
2. Porovnání GIT toxicity přípravných režimů BEAM a TEAM před autologní transplantací u pacientů s lymfomy.
3. Prevence a léčba kardiovaskulárních a krvácivých komplikací u nemocných s chronickou lymfocytární leukemií léčených inhibitory Brutonovy kinázy.
4. CD34+ cell content in unrelated allogeneic peripheral blood stem cell grafts transported internationally. Does the inter-laboratory variability affect comparability of graft quality data?
5. Invariantní NKT buňky a jejich využití pro imunomodulaci GvHD - souhrn literatury a preklinická data.
6. Allogeneic BMT in patients above 45 years of age: a single center experience
7. CD34+ cell content in unrelated allogeneic peripheral blood stem cell grafts transported internationally. Are collection and transplantation centersʼ results comparable?: P1119
8. Interlaboratory variability of CD34+ stem cell enumeration. A pilot study to national external quality assessment within the Czech Republic
9. Distribution of KIR genes in the population of unrelated individuals homozygous for ancestral haplotype AH8.1 (HLA-A1B8DR3)
10. No benefit of autologous stem cell transplantation as consolidation for high and high-intermediate risk diffuse large B-cell lymphoma in 1.CR after R-CHOP therapy - A single-centre experience: R1286
11. Reduced-intensity transplantation in patients older than 60 years of age with high-risk or advanced acute myeloid leukaemia - single-centre experience
12. Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF
13. Age-related differencies in healthy donors PBSC mobilisation. A single-centre experience
14. Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation
15. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie 2021.
16. Odběry kostní dřeně pro alogenní transplantaci - zhodnocení desetileté zkušenosti se zaměřením na využití autotransfuzí u dárců.
17. Externí hodnocení kvality stanovení CD34+ buněk v České a Slovenské republice - dlouhodobé zkušenosti z osmiletého období.
18. Rozvoj rezistentní GvHD u pa-cientky léčené nivolumabem pro relaps Hodgkinova lymfomu po alogenní nepříbuzenské transplantaci.
19. Beneficial Effects of Mesenchymal Stem Cells on Adult Porcine Cardiomyocytes in Non-Contact Co-Culture.
20. Dlouhodobě skladované kryokonzervované transplantáty a jejich likvidace.
21. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL) - 2018.
22. Dospělý onkologický nemocný v intenzivní péči: Je již čas říci „ano, zvážíme to", než říkat „ne"?!
23. Portal vein embolization with stem cells application for enlargement of future liver remnant volume in primary non-resectable colorectal liver metastases
24. P676: LOW‐DOSE FCR COMPARED TO BR IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 ABERRATIONS: A REAL – WORLD RETROSPECTIVE ANALYSIS BY THE CZECH CLL STUDY GROUP.
25. Léčba chronické lymfocytární leukemie s aberací TP53.
26. Hodnocení exprese antigenu CD45 u pacientů s mnohočetným myelomem a jeho vliv na dobu do první progrese nebo relapsu.
27. Vysoce riziková chronická lymfocytární leukemie -- charakteristika a léčebné možnosti.
28. PSY26 Cost-Effectiveness of Hematopoietic Stem Cell Mobilization Strategies in Multiple Myeloma and Lymphoma Patients in Czech Republic
29. Mobilizace krvetvorných buněk pomocí plerixaforu - zkušenosti transplantačních center v České republice.
30. Spontánní remise akutní myeloidní leukemie -- klinické případy jednoho centra.
31. Lymphocyte profile in peripheral blood of patients with multiple myeloma.
32. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
33. Allogeneic stem cell transplantation in patients with multiple myeloma-single center experience.
34. Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.
35. COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
36. Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies.
37. Should We Stop Collecting the Preoperative Autologous Blood before Bone Marrow Harvest?
38. Mesenchymal Stromal Cell Therapy in Novel Porcine Model of Diffuse Liver Damage Induced by Repeated Biliary Obstruction.
39. Dynamic Changes of Inhibitory Killer-Immunoglobulin-Like Receptors on NK Cells after Allogeneic Hematopoietic Stem Cell Transplantation: An Initial Study.
40. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
41. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome.
42. Growth of colorectal liver metastases is not accelerated by intraportal administration of stem cells after portal vein embolization.
43. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.
44. [Hemophagocytic lymfohistiocytosis in adults: review and case report].
45. Portal Vein Embolization with Contralateral Application of Stem Cells Facilitates Increase of Future Liver Remnant Volume in Patients with Liver Metastases.
46. Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.
47. Validation of shortened 2-day sterility testing of mesenchymal stem cell-based therapeutic preparation on an automated culture system.
48. The Quality Control of Mesenchymal Stromal Cells by in Vitro Testing of Their Immunomodulatory Effect on Allogeneic Lymphocytes.
49. [Treatment of Chronic Lymphocytic Leukemia with TP53 Aberrations].
50. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.